Supportive care for chimeric antigen receptor T-cell patients

Area of Science:

• Oncology
• Immunotherapy
• Hematology

Background:

• Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of relapsed/refractory B-cell malignancies.
• The CAR-T field is rapidly expanding, with new products targeting indications like multiple myeloma and increasing patient eligibility.
• CAR-T therapy presents logistical challenges, often requiring extended hospital stays and posing risks of severe immune side effects and prolonged cytopenias.

Approach:

• This review provides comprehensive guidance on supportive management for health professionals delivering CAR-T therapy.
• It covers the entire CAR-T pathway, from initial referral through long-term follow-up.
• Emphasis is placed on addressing psychosocial aspects alongside clinical care.

Key Points:

• Standardized and comprehensive supportive care is critical for safe CAR-T therapy delivery.
• Patients must be fully informed about the risks, benefits, and extended hospital admission requirements.
• Effective supportive care maximizes the potential of this transformative treatment modality.

Conclusions:

• Optimal supportive care is essential for navigating the complexities of CAR-T therapy.
• Addressing both clinical and psychosocial needs ensures patient safety and treatment efficacy.
• This guidance aims to enhance the delivery and outcomes of CAR-T therapy for eligible patients.